Article Text

Download PDFPDF
Long-term outcome after catheter ablation for atrial fibrillation: safety, efficacy and impact on prognosis
  1. Ross J Hunter,
  2. Richard J Schilling
  1. Cardiology Research Department, Barts and The London NHS Trust and QMUL, St Bartholomew's Hospital, West Smithfield, London, UK
  1. Correspondence to Professor Richard J Schilling, Cardiology Research Department, Barts and The London NHS Trust and QMUL, St Bartholomew's Hospital, First Floor Dominion House, 60 Bartholomew Close, West Smithfield, London EC1A 7BE, UK; r.schilling{at}qmul.ac.uk

Abstract

Catheter ablation of atrial fibrillation (AF) continues to expand and evolve. Large registries like the worldwide survey have provided insight into methods, safety and efficacy of catheter ablation for AF in the short term, and how these are changing. Long-term follow-up data are also emerging answering important questions about safety and efficacy over subsequent years. A small number of studies have attempted to examine whether catheter ablation of AF impacts on hard end points such as stroke and death and hence improve prognosis. This article reviews the current literature providing insight into these rapidly changing areas.

  • AF
  • outcome
  • efficacy
  • safety
  • prognosis
  • atrial arrhythmias
  • radiofrequency ablation (rfa)
  • atrial fibrillation

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Funding RJH is supported by a grant from the British Heart Foundation (PG/08/130).

  • Competing interests RJS is a member of the scientific advisory board for Biosense Webster. He is listed on the Speakers Bureau for Endocardial Solutions and has received payment for lectures sponsored by them. RJH and RJS have also received support for travel to international meetings from Guidant, Medtronic, St Jude Medical, Endocardial Solutions and Biosense Webster.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles